Biotech Industry Financials, Performance and Ratios
-
Industry Score
36.7 /100
Rank 64 out of 131 Industries -
Advance/Decline
190/84
-
No. of Companies274
-
Avg. Market Cap2,883
-
Price to Earning Ratio5.86
-
Price to Earning Growth Ratio0.36
-
Price to Book Ratio14.45
-
Return on Equity13.94
-
Return on Capital Employed-
-
Return on Assets4.77
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %51.24 %
-
Net Profit Growth Qtr YoY %-3.66 %
-
Net Profit Growth Qtr QoQ %-90.49 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,410.0
|
23.0
|
L
 0.0%
H
22.9
23.6
|
L
 -1.8%
H
22.4
24.5
|
L
 -8.7%
H
22.4
27.7
|
L
 5.8%
H
21.8
27.7
|
L
 119.8%
H
8.0
27.7
|
L
 142.9%
H
7.9
27.7
|
L
 -33.5%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,546.8
|
4.5
|
L
 0.2%
H
4.4
4.6
|
L
 -3.1%
H
4.3
4.8
|
L
 -22.9%
H
4.2
6
|
L
 -47.7%
H
4.2
9.8
|
L
 107.9%
H
1.5
9.8
|
L
 171.3%
H
1.0
9.8
|
L
 -68.3%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,851.7
|
22.8
|
L
 3.6%
H
22.5
23.0
|
L
 2.9%
H
21.4
24.9
|
L
 20.2%
H
18.5
24.9
|
L
 3.8%
H
18.5
24.9
|
L
 143.6%
H
6.5
26.4
|
L
 34.1%
H
6.5
26.4
|
L
 -35.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
189.0
|
4.0
|
L
 2.6%
H
3.8
4.0
|
L
 6.9%
H
3.8
4.5
|
L
 40.7%
H
2.8
4.5
|
L
 69.9%
H
2.3
4.5
|
L
 102.5%
H
1.4
4.5
|
L
 -50%
H
1.2
8.7
|
L
 -83.7%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,082.3
|
3.6
|
L
 2.3%
H
3.5
3.6
|
L
 3.5%
H
3.4
3.7
|
L
 15.2%
H
3.0
3.8
|
L
 1.7%
H
2.7
4.9
|
L
 41.7%
H
1.9
6.5
|
L
 -52.0%
H
1.9
8.1
|
L
 -90.5%
H
1.9
39.2
|
L
H
1.9
71.9
|
| Arcellx Inc |
|
6,689.5
|
114.4
|
L
H
114.4
114.5
|
L
 0.1%
H
114.2
114.6
|
L
 67.0%
H
63.1
114.8
|
L
 67.4%
H
60.4
114.8
|
L
 59.6%
H
47.9
114.8
|
L
 290.5%
H
27.3
114.8
|
L
H
6.0
114.8
|
L
H
6.0
114.8
|
| Adma Biologics Inc |
|
3,691.5
|
15.5
|
L
 2.3%
H
15.0
15.5
|
L
 0.7%
H
14.9
16.2
|
L
 -3.7%
H
14.6
17.2
|
L
 -21.4%
H
14.6
19.9
|
L
 -15.9%
H
13.8
25.7
|
L
 395.2%
H
2.9
25.7
|
L
 620.9%
H
1.0
25.7
|
L
 202.7%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,038.7
|
13.2
|
L
 0.5%
H
13.2
13.9
|
L
 -10.9%
H
12
15.2
|
L
 -17.5%
H
12
17.0
|
L
 -15.6%
H
12
19.8
|
L
 81.9%
H
6.7
20.8
|
L
 61.1%
H
2.3
20.8
|
L
 -69.1%
H
2.3
47.1
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.4
|
1.7
|
L
 -4.4%
H
1.7
1.8
|
L
 -53.2%
H
1.7
4.4
|
L
 -64.8%
H
1.7
5.0
|
L
 -84.9%
H
1.7
17.6
|
L
 -100.0%
H
1.7
11679.7
|
L
 -100.0%
H
1.7
10000000000
|
L
 -100.0%
H
1.7
10000000000
|
L
H
1.7
10000000000
|
| Agenus Inc |
|
119.6
|
3.3
|
L
 6.8%
H
2.9
3.3
|
L
 11.8%
H
2.9
3.6
|
L
 13.4%
H
2.9
3.6
|
L
 -10.8%
H
2.7
4.9
|
L
 78.0%
H
1.4
7.3
|
L
 -91.1%
H
1.4
196
|
L
 -95.0%
H
1.4
196
|
L
 -95.4%
H
1.4
196
|
| Avalon GloboCare Corp |
|
3.8
|
0.7
|
L
 -4.4%
H
0.7
0.7
|
L
 -28.3%
H
0.6
0.9
|
L
 -25%
H
0.4
1.6
|
L
 -34.7%
H
0.4
1.6
|
L
 -86.5%
H
0.4
7.9
|
L
 -73.3%
H
0.2
11.7
|
L
 -94.8%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
256.4
|
4.3
|
L
 3.4%
H
4.3
4.5
|
L
 -11.3%
H
4.0
5.6
|
L
 -19.3%
H
4.0
5.7
|
L
 6.8%
H
3.9
5.9
|
L
 -38.4%
H
1.1
7.0
|
L
 -45.5%
H
1.1
12.0
|
L
 -64.4%
H
1.1
16.0
|
L
 -10.1%
H
1.1
16.7
|
| Alector Inc |
|
248.3
|
2.3
|
L
 2.3%
H
2.2
2.3
|
L
 12.5%
H
1.9
2.7
|
L
 20.3%
H
1.9
2.7
|
L
 58.5%
H
1.3
2.7
|
L
 55.2%
H
0.9
3.4
|
L
 -65.1%
H
0.9
9.1
|
L
 -87.9%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
557.3
|
2.5
|
L
 3.3%
H
2.4
2.5
|
L
 7.8%
H
2.2
2.7
|
L
 37.8%
H
1.8
2.8
|
L
 68.7%
H
1.3
2.8
|
L
 27.8%
H
0.9
2.8
|
L
 -56.2%
H
0.9
6.9
|
L
 -93.6%
H
0.9
39.1
|
L
H
0.9
55
|
| Altimmune Inc |
|
448.3
|
3.6
|
L
 2.3%
H
3.5
3.6
|
L
 1.1%
H
3.5
4.0
|
L
 -21.0%
H
3.4
4.8
|
L
 -32.2%
H
3.4
6.4
|
L
 -39.5%
H
2.9
7.7
|
L
 -67.2%
H
2.1
14.8
|
L
 -79.8%
H
2.1
23.5
|
L
 -99.3%
H
1.5
1050
|
| Alvotech |
|
1,112.4
|
3.6
|
L
 2.9%
H
3.5
3.6
|
L
 -11.0%
H
3.5
4.1
|
L
 -23.1%
H
3.5
4.7
|
L
 -33.9%
H
3.5
5.6
|
L
 -68.4%
H
3.5
11.9
|
L
 -72.8%
H
3.5
18
|
L
H
3.5
18
|
L
H
3.5
18
|
| Kalaris Therapeutics Inc |
|
158.2
|
8.5
|
L
 -2.4%
H
8.4
9.0
|
L
 -13.9%
H
8.4
10.2
|
L
 -2.2%
H
8.1
11.2
|
L
 -0.5%
H
7.9
11.9
|
L
 -12.3%
H
2.1
12.9
|
L
 68.2%
H
0.4
12.9
|
L
 -70.7%
H
0.4
30.2
|
L
H
0.4
49.0
|
| Amgen |
|
197,110.1
|
365.7
|
L
 -0.2%
H
365.2
370.9
|
L
 -1.1%
H
365.2
380.1
|
L
 -1.0%
H
361.4
391.3
|
L
 12.4%
H
318.2
391.3
|
L
 16.6%
H
261.4
391.3
|
L
 55.7%
H
211.7
391.3
|
L
 55.0%
H
198.6
391.3
|
L
 155.3%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,882.4
|
65.5
|
L
 1.0%
H
63.6
66.7
|
L
 18.2%
H
55.3
66.7
|
L
 23.4%
H
52.7
66.7
|
L
 43.7%
H
42
66.7
|
L
 291.4%
H
15.3
66.7
|
L
 185.1%
H
12.2
66.7
|
L
 230.5%
H
12.2
66.7
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,606.0
|
71.7
|
L
 1.7%
H
70.4
72.3
|
L
 -3.2%
H
70.2
77.5
|
L
 -7.4%
H
70.2
80.1
|
L
 -12.1%
H
70.2
87.1
|
L
 14.7%
H
56.7
99.5
|
L
 79.1%
H
36.5
99.5
|
L
 117.1%
H
22.3
99.5
|
L
 115.7%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
94.1
|
2.8
|
L
 -0.4%
H
2.8
2.9
|
L
 -1.1%
H
2.8
3.1
|
L
H
2.7
3.1
|
L
 -13.5%
H
2.7
3.6
|
L
 -4.7%
H
2.3
5.5
|
L
 -32.5%
H
2.1
6.5
|
L
 -51.0%
H
2.1
8.1
|
L
 -5.4%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
124.7
|
4.6
|
L
 -7.9%
H
4.4
5.2
|
L
 59.7%
H
3.0
6.9
|
L
 329.3%
H
1
6.9
|
L
 288.9%
H
1
6.9
|
L
 225%
H
1
6.9
|
L
 -43.4%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
4.3
|
0.8
|
L
 4.0%
H
0.8
0.8
|
L
 12.9%
H
0.7
0.8
|
L
 -6.0%
H
0.6
0.9
|
L
 -67.2%
H
0.6
2.6
|
L
 -97.7%
H
0.6
35.9
|
L
 -100.0%
H
0.6
27900
|
L
 -100.0%
H
0.6
149400
|
L
 -100.0%
H
0.6
2244000
|
| Aptevo Therapeutics Inc |
|
7.3
|
4.7
|
L
 5.7%
H
4.4
4.7
|
L
 -27.0%
H
4.0
6.7
|
L
 -30.4%
H
4.0
7.7
|
L
 -75.1%
H
4.0
20.0
|
L
 -99.5%
H
4.0
1299.6
|
L
 -100.0%
H
4.0
1233639.7
|
L
 -100.0%
H
4.0
22798512
|
L
H
4.0
68020444.8
|
| AquaBounty Tech Inc |
|
3.6
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -1.1%
H
0.9
1
|
L
 2.2%
H
0.9
1.1
|
L
 2.2%
H
0.8
1.2
|
L
 43.8%
H
0.5
3.0
|
L
 -92.1%
H
0.5
12.7
|
L
 -99.4%
H
0.5
162.8
|
L
H
0.5
610
|
| Arvinas Inc |
|
789.9
|
12.4
|
L
 1.4%
H
12.3
12.5
|
L
 -9.2%
H
11.9
14.5
|
L
 6.0%
H
11
14.5
|
L
 0.1%
H
11
14.5
|
L
 46.5%
H
5.9
14.5
|
L
 -58.2%
H
5.9
53.1
|
L
 -84.1%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
7,993.0
|
57.1
|
L
 3.7%
H
55.8
57.5
|
L
 -4.6%
H
54.0
61.0
|
L
 -10.6%
H
54.0
67.2
|
L
 -16.6%
H
54.0
76.8
|
L
 271.6%
H
9.6
76.8
|
L
 125.4%
H
9.6
76.8
|
L
 -20.6%
H
9.6
93.7
|
L
 1252.6%
H
1.2
93.7
|
| LeonaBio Inc |
|
79.0
|
8.5
|
L
 10.4%
H
6.9
8.5
|
L
 59.6%
H
5.3
8.5
|
L
 94.9%
H
4.2
8.5
|
L
 119.7%
H
3.8
8.5
|
L
 152.5%
H
2.2
8.5
|
L
 -68.6%
H
2.2
43.0
|
L
 -96.0%
H
2.2
236.4
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
1,912.1
|
14.4
|
L
 3.1%
H
14.1
14.4
|
L
 0.4%
H
13.9
14.9
|
L
 1.1%
H
13.5
15.2
|
L
 -8.4%
H
13.5
16.5
|
L
 76.2%
H
6.8
16.5
|
L
 51.4%
H
4.7
16.5
|
L
 0.9%
H
4.1
34.0
|
L
 366.9%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
405.8
|
6.4
|
L
 7.6%
H
5.9
6.5
|
L
 14.1%
H
5.3
6.5
|
L
 14.7%
H
4.9
6.5
|
L
 1.0%
H
4.7
6.5
|
L
 -13.1%
H
4.3
7.7
|
L
 -37.2%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
629.0
|
33.5
|
L
 0.6%
H
32.9
34.5
|
L
 -6.6%
H
31.4
35.8
|
L
 50.4%
H
20.5
36.0
|
L
 82.2%
H
16.8
36.0
|
L
 30.7%
H
13.7
36.0
|
L
 127.0%
H
1.4
61.1
|
L
 -78.6%
H
1.4
167.2
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
710.2
|
14.4
|
L
 3.5%
H
13.7
15.2
|
L
 2.5%
H
13.4
15.3
|
L
 -4.2%
H
13.1
16.4
|
L
 -5.6%
H
12.5
17.7
|
L
 -83.3%
H
6.6
100.1
|
L
 -98.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
438.3
|
4.7
|
L
 1.7%
H
4.7
4.8
|
L
 1.7%
H
4.4
4.9
|
L
 20.4%
H
3.9
5.2
|
L
 14.3%
H
3.5
5.4
|
L
 -49.8%
H
2.9
14.0
|
L
 -49.5%
H
2.9
14.4
|
L
 -68.1%
H
2.9
31.5
|
L
 4.6%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,100.6
|
158.4
|
L
 1.5%
H
155.9
159.2
|
L
 -2.5%
H
153.4
169.1
|
L
 -12.6%
H
153.4
186.3
|
L
 8.3%
H
145.1
191.5
|
L
 29.9%
H
87.0
191.5
|
L
 155.7%
H
55.0
191.5
|
L
 142.8%
H
19.4
191.5
|
L
 1452.5%
H
1.9
191.5
|
| Akari Therapeutics PLC (ADR) |
|
9.6
|
0.2
|
L
 -8.7%
H
0.2
0.2
|
L
 -16%
H
0.2
0.3
|
L
 -8.7%
H
0.2
0.3
|
L
 -48.8%
H
0.2
0.3
|
L
 -80.6%
H
0.2
1.7
|
L
 -95.9%
H
0.2
5.7
|
L
 -99.7%
H
0.2
66.4
|
L
 -99.9%
H
0.2
444
|
| Autolus Therapeutics PLC (ADR) |
|
393.9
|
1.5
|
L
 2.8%
H
1.5
1.5
|
L
 -2.0%
H
1.4
1.7
|
L
 5.7%
H
1.4
1.9
|
L
 -8.6%
H
1.3
2.1
|
L
 -20.9%
H
1.1
2.7
|
L
 -29.2%
H
1.1
7.5
|
L
 -77.7%
H
1.1
8.2
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
13,754.6
|
71.0
|
L
 2.2%
H
70.1
72.0
|
L
 8.6%
H
64.5
75.9
|
L
 -5.7%
H
62.8
76.8
|
L
 -4.8%
H
62.8
84.9
|
L
 115.2%
H
28.3
84.9
|
L
 397.9%
H
11.8
84.9
|
L
 1.5%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
13.4
|
0.2
|
L
 12.5%
H
0.2
0.2
|
L
 5.9%
H
0.2
0.2
|
L
 20%
H
0.1
0.3
|
L
 -76.6%
H
0.1
0.8
|
L
 -47.1%
H
0.1
1.4
|
L
 -93.0%
H
0.1
4.1
|
L
 -99.7%
H
0.1
76.6
|
L
H
0.1
76.6
|
| BioCardia Inc |
|
13.5
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 7.6%
H
1.1
1.3
|
L
 11.4%
H
1.1
1.4
|
L
 -2.3%
H
1.1
1.4
|
L
 -51.2%
H
1
3.2
|
L
 -95.7%
H
1
43.8
|
L
 -97.9%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,272.3
|
9.1
|
L
 10.2%
H
8.2
9.6
|
L
 6.8%
H
8.2
9.6
|
L
 34.0%
H
6.8
9.6
|
L
 19.4%
H
6.2
9.6
|
L
 17.7%
H
6
11.3
|
L
 8.2%
H
4.0
11.3
|
L
 -32.8%
H
4.0
20.0
|
L
 255.3%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
30.5
|
4.2
|
L
 -0.2%
H
4.2
4.4
|
L
 9.1%
H
3.7
4.4
|
L
 3.4%
H
3.6
4.4
|
L
 -53.1%
H
3.6
12.1
|
L
 -98.9%
H
3.6
982
|
L
 -100.0%
H
3.6
11514
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
138373.2
|
| Black Diamond Therapeutics Inc |
|
125.9
|
2.2
|
L
 4.3%
H
2.1
2.2
|
L
 2.8%
H
2.0
2.3
|
L
 -0.5%
H
1.9
2.6
|
L
 -16.6%
H
1.9
2.9
|
L
 28.5%
H
1.2
4.9
|
L
 31.5%
H
1.2
7.7
|
L
 -91.5%
H
1.2
29.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,601.4
|
25.5
|
L
 1.5%
H
25.5
26.1
|
L
 -3.8%
H
24.6
27.9
|
L
 -8.5%
H
24.6
34.2
|
L
 -4.8%
H
24.3
36.4
|
L
 5.4%
H
13.5
36.4
|
L
 -27.2%
H
13.5
49.5
|
L
 -73.1%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
26,862.7
|
183.0
|
L
 0.8%
H
181.9
184.6
|
L
 -1.0%
H
181.5
193.0
|
L
 -6.9%
H
181.2
200.3
|
L
 4.2%
H
160.4
202.4
|
L
 31.3%
H
110.0
202.4
|
L
 -30.2%
H
110.0
319.8
|
L
 -29.6%
H
110.0
468.6
|
L
 -20.6%
H
110.0
468.6
|
| BioVie Inc |
|
10.8
|
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 5.2%
H
1.3
1.5
|
L
 12.6%
H
1.2
1.5
|
L
H
1.1
1.5
|
L
 -86.8%
H
1.1
13.2
|
L
 -99.9%
H
1.1
1139
|
L
 -99.9%
H
1.1
2386
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
11,052.8
|
57.5
|
L
 -1.8%
H
55.9
58.8
|
L
 -6.0%
H
55.9
62.0
|
L
 -4.0%
H
55.9
66.3
|
L
 10.3%
H
51.5
66.3
|
L
 -17.2%
H
50.8
73.2
|
L
 -34.5%
H
50.8
100.4
|
L
 -26.7%
H
50.8
117.8
|
L
 -31.1%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
11.3
|
1.1
|
L
H
1.1
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -27.9%
H
1.1
1.8
|
L
 -68.0%
H
1.1
5.5
|
L
 -90.8%
H
0.1
12.1
|
L
 -98.9%
H
0.1
96.6
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
406.9
|
11.9
|
L
 1.1%
H
11.4
12.1
|
L
 4.8%
H
11.3
13.4
|
L
 14.5%
H
9.9
13.4
|
L
 -2.5%
H
9.9
14.4
|
L
 -20.6%
H
9.9
17.2
|
L
 197%
H
1.9
17.2
|
L
 -78.6%
H
1.9
178.3
|
L
 -97.2%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
12.2
|
1.5
|
L
 1.4%
H
1.4
1.6
|
L
 2.7%
H
1.3
1.6
|
L
 -8.5%
H
1.3
1.7
|
L
 -14.3%
H
1.3
1.9
|
L
 -95.8%
H
1.1
21.8
|
L
 -99.6%
H
1.1
430
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
34.1
|
1.6
|
L
 4.7%
H
1.5
1.6
|
L
 5.4%
H
1.4
1.8
|
L
 -1.3%
H
1.4
1.8
|
L
 -16.6%
H
1.4
2.1
|
L
 -26.8%
H
1.2
8.1
|
L
 -92.0%
H
0.2
29.6
|
L
 -96.8%
H
0.2
49.2
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
345.5
|
5.0
|
L
 4.2%
H
4.8
5.0
|
L
 -4.2%
H
4.8
5.5
|
L
 -5.0%
H
4.8
5.9
|
L
 -32.1%
H
4.8
7.5
|
L
 -48.6%
H
4.8
10.1
|
L
 -76.8%
H
4.8
28.9
|
L
 -82.5%
H
4.8
62.1
|
L
H
4.8
62.1
|
| BioNTech SE (ADR) |
|
22,990.3
|
91.6
|
L
 0.5%
H
90.8
92.8
|
L
 -9.7%
H
79.5
102.9
|
L
 -13.5%
H
79.5
112.4
|
L
 -2.3%
H
79.5
124
|
L
 -7.9%
H
79.5
124
|
L
 -29.5%
H
76.5
136.9
|
L
 -15.1%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
307.1
|
3.2
|
L
 4.3%
H
3.1
3.3
|
L
 0.6%
H
3.0
3.5
|
L
 13.9%
H
2.8
3.8
|
L
 33.5%
H
2
3.8
|
L
 75.3%
H
1.0
3.8
|
L
 -57.0%
H
1.0
26.4
|
L
 -72.9%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
14.0
|
0.9
|
L
 7.2%
H
0.8
0.9
|
L
 21.9%
H
0.7
0.9
|
L
 34.9%
H
0.5
0.9
|
L
 -80.8%
H
0.5
7.2
|
L
 -55.1%
H
0.5
7.2
|
L
 -87.5%
H
0.5
8.6
|
L
 -99.3%
H
0.5
121.1
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
36.5
|
3.9
|
L
 -0.8%
H
3.9
4.0
|
L
 -1.0%
H
3.6
4
|
L
 4.6%
H
3.5
4.2
|
L
 -7.8%
H
3.5
4.9
|
L
 -74.7%
H
3.5
43.7
|
L
 -98.1%
H
3.5
211.3
|
L
 -99.4%
H
3.5
1067.3
|
L
 -97.7%
H
3.5
1067.3
|
| Crescent Biopharma Inc |
|
-
|
11.6
|
L
 3.3%
H
11.3
11.8
|
L
 -4.3%
H
11.2
13.3
|
L
 29.2%
H
8.8
13.5
|
L
 -12.6%
H
8.7
14.7
|
L
 1.8%
H
7.6
21.4
|
L
 256.5%
H
2.8
21.4
|
L
 -20.6%
H
0.9
21.4
|
L
 -83.0%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
276.1
|
2.8
|
L
 4.0%
H
2.7
2.9
|
L
 -6.9%
H
2.7
3.8
|
L
 49.7%
H
1.8
3.8
|
L
 16.5%
H
1.7
3.8
|
L
 39.4%
H
1.1
3.8
|
L
 -34.3%
H
1.1
11.9
|
L
 -93.6%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
210.9
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 7.2%
H
2.0
2.4
|
L
 35.2%
H
1.6
2.4
|
L
 48.7%
H
1.4
2.4
|
L
 35.2%
H
1.1
2.4
|
L
 193.4%
H
0.5
3.0
|
L
 -76.1%
H
0.5
9.6
|
L
 -58.2%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
92.7
|
1.1
|
L
H
1.1
1.1
|
L
 1.9%
H
1
1.2
|
L
 -6.3%
H
1
1.2
|
L
 -34.4%
H
1.0
1.7
|
L
 133.3%
H
0.2
3.8
|
L
 -36.4%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
5.4
|
2.6
|
L
 -7.5%
H
2.4
2.7
|
L
 9.8%
H
2.4
3.9
|
L
 9.8%
H
2.4
3.9
|
L
 -68.0%
H
2.4
9
|
L
 -82.2%
H
2.4
46.5
|
L
 -97.0%
H
2.4
89.7
|
L
 -99.4%
H
2.4
449.1
|
L
H
2.4
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
69.1
|
12
|
L
 -0.3%
H
11.7
12.2
|
L
 -9.0%
H
11
14
|
L
 -0.9%
H
11
14
|
L
 -20.5%
H
10.5
16.0
|
L
 8.5%
H
6.3
21.4
|
L
 -55.6%
H
2.3
43.8
|
L
 21.2%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,796.0
|
35.7
|
L
 5.0%
H
35.2
37.2
|
L
 -3.7%
H
33.6
38.2
|
L
 -2.2%
H
33.6
40.5
|
L
 -11.3%
H
32.9
41.4
|
L
 400.1%
H
3.7
43.7
|
L
 193.7%
H
3.7
43.7
|
L
 328.7%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
180.4
|
1.9
|
L
 2.7%
H
1.9
2
|
L
 6.0%
H
1.8
2.1
|
L
 22.2%
H
1.5
2.2
|
L
 12.9%
H
1.4
2.2
|
L
 91.1%
H
0.7
3.5
|
L
 -62.6%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
112.8
|
1.0
|
L
 -1.0%
H
1
1.0
|
L
 4.1%
H
1.0
1.1
|
L
 -2.9%
H
1.0
1.1
|
L
 -1.9%
H
0.9
1.1
|
L
 -10.6%
H
0.8
1.6
|
L
 106.1%
H
0.5
3.1
|
L
 -77.0%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
12.2
|
0.9
|
L
 -6.3%
H
0.9
1.0
|
L
 -10.1%
H
0.9
1.1
|
L
 -22.6%
H
0.9
1.2
|
L
 -25.2%
H
0.8
1.2
|
L
 -68.7%
H
0.8
3.2
|
L
 -91.6%
H
0.8
20
|
L
 -99.6%
H
0.8
348
|
L
 -99.4%
H
0.8
372
|
| CorMedix Inc |
|
517.0
|
6.5
|
L
 1.4%
H
6.5
6.6
|
L
 1.2%
H
6.1
6.9
|
L
 -10.9%
H
6.1
7.5
|
L
 -42.3%
H
6.1
13.0
|
L
 -37.5%
H
5.6
17.4
|
L
 85.3%
H
2.6
17.4
|
L
 -29.4%
H
2.6
17.4
|
L
 -42.6%
H
0.9
22.7
|
| CRISPR Therapeutics AG |
|
4,580.4
|
47.7
|
L
 -2.1%
H
47.7
50.1
|
L
 -15.5%
H
47.5
59.1
|
L
 -10.1%
H
47.5
61.8
|
L
 -15.2%
H
45.5
61.8
|
L
 13.3%
H
30.0
78.5
|
L
 6.2%
H
30.0
91.1
|
L
 -64.3%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
85.4
|
6.2
|
L
 0.8%
H
6.0
6.3
|
L
 4.8%
H
5.5
6.3
|
L
 1.2%
H
5.5
6.3
|
L
 -21.2%
H
5.5
7.8
|
L
 -33.4%
H
5.5
10.3
|
L
 50%
H
3.6
12.0
|
L
 -55.1%
H
3.6
14.7
|
L
 75.7%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
28.3
|
0.3
|
L
 10.7%
H
0.3
0.3
|
L
 3.3%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -32.6%
H
0.2
0.5
|
L
 -67.7%
H
0.2
1.1
|
L
 -90.1%
H
0.2
5.1
|
L
 -97.9%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
18.1
|
7.8
|
L
 4.7%
H
7.4
7.9
|
L
 -6.4%
H
7.2
8.4
|
L
 39.9%
H
4.9
9.0
|
L
 -36.9%
H
4.9
9.6
|
L
 -59.4%
H
4.9
20.4
|
L
 390.5%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.6
|
2.1
|
L
 12.0%
H
1.9
2.1
|
L
 9.0%
H
1.8
2.2
|
L
 35.8%
H
1.4
2.2
|
L
 -0.5%
H
1.4
2.2
|
L
 -63.7%
H
1.4
6.1
|
L
 -66.1%
H
1.4
10.2
|
L
 -99.3%
H
1.4
524.8
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
714.0
|
6.3
|
L
 -1.6%
H
6.3
6.5
|
L
 -4.4%
H
6.3
7.6
|
L
 8.3%
H
6.3
8.9
|
L
 -4.6%
H
5.7
8.9
|
L
 80.8%
H
2.3
8.9
|
L
 -23.5%
H
2.3
12.8
|
L
 -85.2%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,336.8
|
21.0
|
L
 2.3%
H
20.3
21.1
|
L
 6.9%
H
20
21.8
|
L
 12.1%
H
18.7
22.6
|
L
 21.3%
H
15.3
23.8
|
L
 38.9%
H
10.6
23.8
|
L
 -11.7%
H
10.6
33.3
|
L
 -66.1%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
49.3
|
3.0
|
L
 -1.0%
H
3.0
3.3
|
L
 2.0%
H
2.8
3.5
|
L
 -11.1%
H
2.8
3.6
|
L
 -29.6%
H
2.8
5.1
|
L
 -35.5%
H
2.8
8.4
|
L
 -16.9%
H
0.8
13.6
|
L
 -86.9%
H
0.8
24.1
|
L
 -97.9%
H
0.8
308.4
|
| DarioHealth Corp |
|
58.1
|
8.6
|
L
 -4.4%
H
8.3
9.1
|
L
 -11.3%
H
8.3
9.8
|
L
 -26.6%
H
8.3
12.1
|
L
 -28.3%
H
8.3
13.6
|
L
 -35.4%
H
5.9
17.7
|
L
 -89.4%
H
5.9
91.6
|
L
 -97.8%
H
5.9
533
|
L
 -99.4%
H
5.9
2360.0
|
| Bright Minds Biosciences Inc |
|
733.8
|
75.0
|
L
 4.1%
H
73.4
76.8
|
L
 -2.5%
H
69.0
84.3
|
L
 -3.8%
H
69.0
91
|
L
 -12.5%
H
69.0
123.8
|
L
 109.6%
H
23.2
123.8
|
L
 3024.2%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
606.7
|
10.7
|
L
 5.2%
H
10.2
10.9
|
L
 6.0%
H
9.7
10.9
|
L
 5.8%
H
9.7
11.1
|
L
 16.8%
H
8.2
11.1
|
L
 126.6%
H
2.6
11.1
|
L
 51.9%
H
1.9
11.1
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
153.6
|
6.4
|
L
 12.5%
H
5.5
6.5
|
L
 38.4%
H
4.5
6.5
|
L
 64.0%
H
3.7
6.5
|
L
 32.9%
H
3.5
6.5
|
L
 26.6%
H
3.5
8.8
|
L
 608.9%
H
0.3
19.4
|
L
 -46.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,018.3
|
18.3
|
L
 2.1%
H
18.1
18.9
|
L
 23.1%
H
15.0
20.0
|
L
 17.7%
H
14
20.0
|
L
 -6.6%
H
14
21
|
L
 51.8%
H
6.4
25
|
L
 44.8%
H
6.4
47.5
|
L
 9.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
246.6
|
2.5
|
L
 3.3%
H
2.5
2.6
|
L
 26%
H
2.0
2.8
|
L
 43.2%
H
1.7
2.8
|
L
 3.3%
H
1.7
2.8
|
L
 72.6%
H
0.9
4.5
|
L
 -70.1%
H
0.9
11.9
|
L
 -94.7%
H
0.9
73.0
|
L
 -92.2%
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
210.9
|
12.2
|
L
 0.2%
H
11.6
12.7
|
L
 5.1%
H
10.7
13.6
|
L
 42.9%
H
8.4
14.9
|
L
 43.4%
H
7.4
14.9
|
L
 57.7%
H
4.6
14.9
|
L
 142.5%
H
3.0
24.4
|
L
 -94.1%
H
3.0
215
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,645.7
|
27.5
|
L
 -0.9%
H
27.5
28.9
|
L
 -6.5%
H
27.4
31.0
|
L
 3.0%
H
25.3
31.0
|
L
 60.3%
H
14.8
31.0
|
L
 32.7%
H
13.3
31.0
|
L
 29.3%
H
9.8
31.0
|
L
 -36.9%
H
3.9
44.2
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
347.8
|
7.3
|
L
 3.6%
H
7.0
7.4
|
L
 1.4%
H
6.8
8.0
|
L
 28.4%
H
5.2
8.0
|
L
 91.1%
H
3.5
8.0
|
L
 439.3%
H
1.1
8.0
|
L
 139.5%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
254.0
|
1.1
|
L
 2.9%
H
1.0
1.1
|
L
 -6.1%
H
1.0
1.2
|
L
 -3.6%
H
1
1.3
|
L
 24.4%
H
0.7
1.3
|
L
 -12.3%
H
0.7
2.1
|
L
 -70.2%
H
0.7
4.6
|
L
 -92.4%
H
0.7
14.8
|
L
 -99.0%
H
0.7
318
|
| Ensysce Biosciences Inc |
|
1.5
|
0.4
|
L
H
0.4
0.4
|
L
 -25.5%
H
0.4
0.6
|
L
 -6.8%
H
0.3
0.8
|
L
 -67.2%
H
0.3
1.3
|
L
 -89.5%
H
0.3
4.9
|
L
 -94.4%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
132.1
|
2.2
|
L
 -12.2%
H
2.2
2.7
|
L
 22.6%
H
1.7
2.7
|
L
 38.2%
H
1.5
2.7
|
L
 77.9%
H
1.0
2.7
|
L
 185.5%
H
0.3
2.7
|
L
 261.7%
H
0.3
3.3
|
L
 -73.9%
H
0.3
8.3
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,247.1
|
30.3
|
L
 2.3%
H
29.8
30.8
|
L
 8.8%
H
27.0
31.4
|
L
 0.9%
H
26.8
31.8
|
L
 26.4%
H
19.8
31.8
|
L
 17.9%
H
10.6
31.8
|
L
 295.7%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
32.1
|
3.9
|
L
 -9.6%
H
3.8
4.2
|
L
 19.6%
H
3.0
4.6
|
L
 15.3%
H
3.0
4.6
|
L
 -33.4%
H
2.9
6.2
|
L
 116.3%
H
1.2
12.2
|
L
 -64.4%
H
0.8
18.5
|
L
 -95.1%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
137.2
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 -11.3%
H
1.1
1.4
|
L
 -5.6%
H
1.1
1.7
|
L
 5.4%
H
1.0
1.7
|
L
 25.5%
H
0.7
1.9
|
L
 -78.8%
H
0.7
8.8
|
L
 -98.7%
H
0.7
97.4
|
L
 -31.8%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
362.4
|
28.9
|
L
 8.2%
H
26.9
29.0
|
L
 0.6%
H
26
30.6
|
L
 -9.9%
H
26
33.0
|
L
 31.7%
H
21.2
35.6
|
L
 398.8%
H
4.9
35.6
|
L
 17.3%
H
4.1
35.6
|
L
 -96.0%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
433.6
|
8.5
|
L
 2.0%
H
8.4
8.7
|
L
 0.2%
H
8.0
9.3
|
L
 -9.1%
H
8.0
10.5
|
L
 -22.4%
H
7.0
11.8
|
L
 106.8%
H
2.2
12.3
|
L
 -51.1%
H
2.2
36.3
|
L
 -82.7%
H
2.2
50.5
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
296.4
|
5.1
|
L
 3.3%
H
4.9
5.1
|
L
 -12.5%
H
4.6
5.8
|
L
 -8.8%
H
4.6
6.0
|
L
 15.8%
H
4.2
7.0
|
L
 14.2%
H
2.9
7.0
|
L
 3.1%
H
2.7
10.2
|
L
 -60.1%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Galectin Therapeutics Inc |
|
203.7
|
3.2
|
L
 2.3%
H
3.1
3.3
|
L
 1.9%
H
2.9
3.5
|
L
 14.5%
H
2.7
3.5
|
L
 -51.5%
H
2.6
7.1
|
L
 88.1%
H
1.1
7.1
|
L
 66.3%
H
0.7
7.1
|
L
 26.4%
H
0.7
7.1
|
L
 135.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
99.6
|
2.6
|
L
 6.6%
H
2.4
2.6
|
L
 -15.1%
H
2.4
3.1
|
L
 43.1%
H
1.8
3.1
|
L
 -34.4%
H
1.6
4.2
|
L
 22.8%
H
1.4
4.3
|
L
 -41.4%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
12.3
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 2.9%
H
1.0
1.1
|
L
 -34.4%
H
0.7
1.7
|
L
 -57.7%
H
0.7
3.7
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
1,076.1
|
1.7
|
L
 6.3%
H
1.6
1.7
|
L
 9.8%
H
1.5
1.7
|
L
 1.8%
H
1.4
2.0
|
L
 26.3%
H
1.3
2.0
|
L
 2.4%
H
1.0
2.0
|
L
 -35.9%
H
1.0
5.3
|
L
 -2.3%
H
1.0
5.3
|
L
 -36.4%
H
0.8
7.0
|
| Gilead Sciences |
|
179,385.3
|
144.5
|
L
 -0.3%
H
142.7
146.1
|
L
 0.4%
H
142.7
149.4
|
L
 -6.8%
H
142.7
156.0
|
L
 20.6%
H
116.9
157.3
|
L
 29.7%
H
93.4
157.3
|
L
 81.4%
H
62.1
157.3
|
L
 129.1%
H
57.2
157.3
|
L
 61.6%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
399.1
|
28.8
|
L
 7.7%
H
27.2
29.3
|
L
 24.8%
H
22.6
29.3
|
L
 7.3%
H
21.6
29.3
|
L
 179.4%
H
10
34.1
|
L
 140.1%
H
7.8
34.1
|
L
 123.0%
H
7.6
34.1
|
L
 0.7%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,269.4
|
16.7
|
L
 3.9%
H
16.3
16.9
|
L
 -6.5%
H
15.7
18.7
|
L
 -7.1%
H
15.7
20.4
|
L
 1.2%
H
13.7
25.8
|
L
 165.6%
H
3.5
25.8
|
L
 155.0%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
3.9
|
1.8
|
L
 2.9%
H
1.7
1.8
|
L
 -1.1%
H
1.7
2.0
|
L
 5.4%
H
1.3
2.0
|
L
 -78.7%
H
1.3
8.5
|
L
 -95.4%
H
1.3
39
|
L
 -99.3%
H
1.3
296.3
|
L
 -99.9%
H
1.3
2812.5
|
L
 -100.0%
H
1.3
379518072.3
|
| Galapagos NV (ADR) |
|
2,152.9
|
32.7
|
L
 3.0%
H
32.2
32.7
|
L
 -0.8%
H
31.6
33.8
|
L
 -3.7%
H
31.6
36.2
|
L
 5.0%
H
30.7
36.2
|
L
 25.6%
H
22.6
37.8
|
L
 -15.5%
H
22.4
45.2
|
L
 -60.7%
H
22.4
83.8
|
L
 -23.5%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
7,652.2
|
64.8
|
L
 1.9%
H
64.1
65.8
|
L
 -3.8%
H
63.2
68.4
|
L
 -18.4%
H
63.2
81.5
|
L
 2.2%
H
63.0
82.2
|
L
 4.1%
H
47.5
82.2
|
L
 61.9%
H
29.9
82.2
|
L
 48.8%
H
29.9
82.2
|
L
 670.1%
H
7.5
82.2
|
| HCW Biologics Inc |
|
4.5
|
0.8
|
L
 51.9%
H
0.7
1.1
|
L
 27.4%
H
0.5
1.1
|
L
 21.5%
H
0.5
1.1
|
L
 -57.8%
H
0.5
1.9
|
L
 -94.2%
H
0.2
17.8
|
L
 -98.5%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Heron Therapeutics Inc |
|
167.8
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 -8.3%
H
0.9
1.0
|
L
 -22.6%
H
0.9
1.3
|
L
 -36.4%
H
0.9
1.6
|
L
 -61.6%
H
0.9
2.6
|
L
 -62.3%
H
0.5
3.9
|
L
 -94.9%
H
0.5
19.0
|
L
 -95.1%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
9.0
|
2.4
|
L
 -5.2%
H
2.3
2.5
|
L
 -32.9%
H
2.1
3.5
|
L
 -35.4%
H
2.1
4
|
L
 -69.7%
H
2.1
11.5
|
L
 -51.9%
H
2.1
38.3
|
L
 -97.2%
H
2.1
136.5
|
L
 -98.3%
H
2.1
200.9
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
221.9
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 3.6%
H
1.1
1.3
|
L
 13.9%
H
1.0
1.3
|
L
 -2.5%
H
0.9
1.3
|
L
 -62.2%
H
0.9
3.4
|
L
 -59.6%
H
0.9
10.0
|
L
 -89.9%
H
0.9
17.5
|
L
H
0.9
17.5
|
| Immucell Corp |
|
57.7
|
6.4
|
L
 0.2%
H
6.3
6.5
|
L
 -3.3%
H
6.3
6.7
|
L
 -3.3%
H
6.2
6.7
|
L
 3.9%
H
5.8
7.1
|
L
 27.9%
H
4.5
7.6
|
L
 27.6%
H
3.3
7.6
|
L
 -39.2%
H
3.3
11.5
|
L
 1.1%
H
3.3
13.2
|
| InflaRx N.V. |
|
63.7
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1.0
|
L
 9.3%
H
0.8
1.0
|
L
 -6%
H
0.8
1.2
|
L
 -21.0%
H
0.7
1.9
|
L
 -47.5%
H
0.7
7.3
|
L
 -80.5%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
69.7
|
6.2
|
L
 5.4%
H
6.1
6.4
|
L
 6.7%
H
5.8
6.5
|
L
 -9.8%
H
5.8
7.3
|
L
 1.0%
H
5.7
7.6
|
L
 -61.3%
H
5.7
18
|
L
 -87.8%
H
5.7
91.7
|
L
H
5.7
451.3
|
L
H
5.7
451.3
|
| Illumina Inc |
|
18,178.3
|
118.9
|
L
 0.0%
H
117.5
122.9
|
L
 -4.6%
H
115.3
125.1
|
L
 1.8%
H
114.0
134.8
|
L
 -11.9%
H
112.7
155.5
|
L
 38.9%
H
68.7
155.5
|
L
 -47.9%
H
68.7
233.4
|
L
 -71.7%
H
68.7
526
|
L
 -20.7%
H
68.7
555.8
|
| Immunome Inc |
|
2,349.8
|
20.8
|
L
 2.0%
H
20.5
21.2
|
L
 -1.3%
H
19.8
22.2
|
L
 -6.3%
H
19.8
23.1
|
L
 -8.3%
H
19.2
27.7
|
L
 136.8%
H
5.2
27.7
|
L
 341.0%
H
4.4
31.0
|
L
 -27.8%
H
2.1
41.7
|
L
H
2.1
63.8
|
| Imunon Inc |
|
10.3
|
3.0
|
L
 1.3%
H
3
3.2
|
L
 -6.5%
H
3.0
3.3
|
L
 -6.8%
H
3.0
3.6
|
L
 -23.7%
H
3.0
4.2
|
L
 -76.7%
H
3.0
47.4
|
L
 -85.3%
H
3.0
54.8
|
L
 -99.4%
H
3.0
526.5
|
L
 -99.9%
H
3.0
5607
|
| Immatics N.V |
|
1,300.4
|
9.7
|
L
 5.0%
H
9.4
10.3
|
L
 -1.6%
H
9.1
10.6
|
L
 -1.4%
H
9.1
10.6
|
L
 -2.8%
H
8.6
10.9
|
L
 113.2%
H
3.3
12.4
|
L
 26.8%
H
3.3
13.8
|
L
 -15.7%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
5,065.9
|
24.9
|
L
 2.0%
H
24.5
25.1
|
L
 -6.6%
H
24.2
26.8
|
L
 -3.3%
H
24.2
29.3
|
L
 -4.3%
H
23.9
29.3
|
L
 27.5%
H
12.7
29.3
|
L
 61.5%
H
12.7
45.6
|
L
 46.6%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
19.9
|
2.0
|
L
 7.9%
H
1.9
2.1
|
L
 18.6%
H
1.7
2.1
|
L
 14.6%
H
1.5
2.1
|
L
 27.5%
H
1.2
2.7
|
L
 827.3%
H
0.1
4.2
|
L
 53.4%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,320.7
|
70.1
|
L
 2.0%
H
67.3
71.0
|
L
 1.3%
H
67.3
75.9
|
L
 -7.5%
H
67.2
84.5
|
L
 -8.0%
H
67.2
94.6
|
L
 397.1%
H
10.8
94.6
|
L
 210.7%
H
10.8
94.6
|
L
 223.0%
H
7.7
94.6
|
L
H
7.7
94.6
|
| MiNK Therapeutics Inc |
|
45.9
|
9.8
|
L
 0.4%
H
9.3
10.1
|
L
 -4.9%
H
9.3
16.9
|
L
 -11.4%
H
9.3
16.9
|
L
 -19.7%
H
9.3
16.9
|
L
 15.2%
H
6.3
76
|
L
 -51.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
36.4
|
1.4
|
L
 4.6%
H
1.3
1.4
|
L
 3.0%
H
1.2
1.5
|
L
 -4.9%
H
1.2
1.5
|
L
 -28.3%
H
1.2
2.0
|
L
 -82.8%
H
1.2
11.6
|
L
 -79.9%
H
1.2
14.7
|
L
 -90.7%
H
1.2
30.4
|
L
H
1.2
30.4
|
| IO Biotech Inc |
|
12.2
|
0.2
|
L
 -10.5%
H
0.1
0.2
|
L
 -43.3%
H
0.1
0.3
|
L
 -54.1%
H
0.1
0.4
|
L
 -76.1%
H
0.1
0.8
|
L
 -80.7%
H
0.1
2.8
|
L
 -92.4%
H
0.1
2.8
|
L
H
0.1
17.9
|
L
H
0.1
17.9
|
| Iovance Biotherapeutics Inc |
|
1,676.7
|
4.1
|
L
 2.8%
H
4.0
4.1
|
L
 -20.7%
H
3.8
5.6
|
L
 58.4%
H
2.5
5.6
|
L
 88.4%
H
2.1
5.6
|
L
 13.4%
H
1.6
5.6
|
L
 -40.3%
H
1.6
18.3
|
L
 -88.3%
H
1.6
35.7
|
L
 -15.9%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
434.9
|
2.4
|
L
 3.4%
H
2.3
2.5
|
L
 -5.5%
H
2.3
3.0
|
L
 38.3%
H
1.7
3.0
|
L
 324.6%
H
0.6
3.0
|
L
 303.3%
H
0.3
3.0
|
L
 -40.0%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,325.5
|
60.9
|
L
 1.5%
H
60.7
62.5
|
L
 -0.4%
H
59
67.2
|
L
 8.9%
H
55.5
69.4
|
L
 -33.8%
H
40
92
|
L
 19.4%
H
30.8
99.5
|
L
 170.8%
H
18.3
99.5
|
L
 -66.1%
H
11.6
186.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
504.8
|
1.8
|
L
 2.9%
H
1.8
1.9
|
L
 -0.6%
H
1.7
2.0
|
L
 14.7%
H
1.5
2.0
|
L
 -19.4%
H
1.5
3.0
|
L
 123.8%
H
0.5
3.1
|
L
 11.2%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,549.7
|
30.6
|
L
 -0.9%
H
30.3
31.2
|
L
 -7.2%
H
30.3
33.9
|
L
 -5.3%
H
30.3
34.9
|
L
 -15.1%
H
30.3
37.3
|
L
 6.2%
H
23.2
40.7
|
L
 -41.9%
H
23.2
77.0
|
L
 -17.2%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
64.8
|
0.4
|
L
 -8.3%
H
0.4
0.5
|
L
 -84.1%
H
0.4
0.6
|
L
 -83.3%
H
0.4
3.0
|
L
 -82.0%
H
0.4
3.3
|
L
 -75.3%
H
0.4
3.5
|
L
 -74.6%
H
0.4
3.9
|
L
 -83.9%
H
0.4
5.4
|
L
 -85.4%
H
0.4
8.0
|
| Inventiva (ADR) |
|
1,245.9
|
6
|
L
 0.2%
H
6.0
6.1
|
L
 -2.1%
H
6.0
6.8
|
L
 -2.8%
H
5.9
7.1
|
L
 33.9%
H
4.1
7.3
|
L
 101.3%
H
2.7
8.0
|
L
 48.9%
H
1.5
8.0
|
L
 -53.1%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
846.8
|
13.9
|
L
 2.5%
H
13.6
14.0
|
L
 0.6%
H
13.4
14.3
|
L
 5.9%
H
12.9
14.5
|
L
 -7.9%
H
12.1
15.5
|
L
 -54.6%
H
12.1
35.3
|
L
 3.5%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
33.9
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 -12.3%
H
1.2
1.4
|
L
 6.1%
H
1.1
1.5
|
L
 -26.2%
H
1.1
2.1
|
L
 -78.0%
H
1.1
7.2
|
L
 -36.3%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
509.9
|
8.8
|
L
 1.6%
H
8.8
9.1
|
L
 -0.2%
H
8.4
9.1
|
L
 4%
H
8.4
9.4
|
L
 21.9%
H
6.9
9.4
|
L
 23.1%
H
5.5
9.4
|
L
 102.3%
H
4.1
9.4
|
L
 38.8%
H
3.7
9.4
|
L
 117.7%
H
3.5
13.3
|
| Kodiak Sciences Inc |
|
1,442.0
|
23.6
|
L
 1.9%
H
23.2
24.2
|
L
 -5.0%
H
22.6
27.3
|
L
 7.0%
H
21.5
28.9
|
L
 2.6%
H
20.9
31.2
|
L
 548.9%
H
1.9
31.2
|
L
 325.6%
H
1.4
31.2
|
L
 -81.5%
H
1.4
137.1
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
7,313.0
|
250.2
|
L
 1.2%
H
246
255.1
|
L
 -1.4%
H
244.5
265.7
|
L
 -9.5%
H
244.5
298.3
|
L
 3.0%
H
231.7
298.3
|
L
 39.5%
H
122.8
298.3
|
L
 240.3%
H
71.3
298.3
|
L
 206.8%
H
38.9
298.3
|
L
H
8.0
298.3
|
| TuHURA Biosciences Inc |
|
115.2
|
2.0
|
L
 7.4%
H
1.9
2.2
|
L
 36%
H
1.5
2.2
|
L
 53.4%
H
1.0
2.2
|
L
 112.5%
H
0.4
2.2
|
L
 -10.5%
H
0.4
4.4
|
L
 -98.2%
H
0.2
209.3
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
764.1
|
8.7
|
L
H
8.6
8.8
|
L
 -3.5%
H
8.5
9.6
|
L
 4.1%
H
7.8
9.6
|
L
 -18.1%
H
7.4
11.3
|
L
 21.2%
H
5.4
12.5
|
L
 -26.0%
H
5.4
24.2
|
L
 -70.4%
H
5.4
30.4
|
L
 113.6%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,604.1
|
80.9
|
L
 2.4%
H
80.1
82.5
|
L
 -3.1%
H
76.9
86.9
|
L
 -1.8%
H
76.9
95.9
|
L
 -5.6%
H
66.2
95.9
|
L
 135.4%
H
19.4
103
|
L
 159.8%
H
9.6
103
|
L
 34.7%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
50.6
|
6.9
|
L
 0.9%
H
6.8
7.0
|
L
 -0.4%
H
6.8
7.3
|
L
 9.7%
H
6.3
7.5
|
L
 10.0%
H
6.0
7.5
|
L
 17.7%
H
3.5
7.5
|
L
 -85.0%
H
0.7
42.3
|
L
 -89.2%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
22.6
|
1.1
|
L
 9.3%
H
1
1.2
|
L
 120.8%
H
0.5
1.2
|
L
 96.3%
H
0.5
1.2
|
L
 92.7%
H
0.5
1.2
|
L
 -37.3%
H
0.5
1.9
|
L
 -96.3%
H
0.5
44
|
L
 -98.6%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
26.9
|
3.1
|
L
 -0.6%
H
3.1
3.2
|
L
 26.6%
H
2.4
3.3
|
L
 1.3%
H
2.4
3.3
|
L
 -22.6%
H
2.4
4.3
|
L
 155.4%
H
0.6
6.3
|
L
 -54.8%
H
0.6
9.6
|
L
 -92.5%
H
0.6
49.5
|
L
 -78.5%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
38.5
|
0.7
|
L
 17.2%
H
0.6
0.7
|
L
 33.3%
H
0.5
0.7
|
L
 -4.2%
H
0.5
0.7
|
L
 -43.3%
H
0.5
1.3
|
L
 70%
H
0.2
3.7
|
L
 -83.5%
H
0.2
10.2
|
L
 -97.2%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
461.0
|
4.5
|
L
 -3.3%
H
4.4
4.8
|
L
 -14.8%
H
4.4
6
|
L
 41.3%
H
2.7
6.4
|
L
 13.5%
H
2.7
6.4
|
L
 71.8%
H
1.6
6.4
|
L
 -23.1%
H
1.6
13.7
|
L
 -74.7%
H
1.5
18.4
|
L
 -93.7%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
435.9
|
20.5
|
L
 -3.4%
H
20.5
21.5
|
L
 -8.6%
H
20.5
27.8
|
L
 -20.6%
H
20.4
27.8
|
L
 -36.7%
H
20.4
45
|
L
 75.4%
H
7.7
45
|
L
 -53.2%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
183.3
|
2.7
|
L
 1.5%
H
2.7
2.8
|
L
 14.7%
H
2.3
2.9
|
L
 25.8%
H
2.0
2.9
|
L
 23.5%
H
1.6
2.9
|
L
 77.3%
H
1.4
4.7
|
L
 25.8%
H
0.8
4.7
|
L
 -70.3%
H
0.8
9.6
|
L
 -99.3%
H
0.8
598.4
|
| Seres Therapeutics Inc |
|
78.9
|
8.7
|
L
 1.0%
H
8.6
9.0
|
L
 -4.5%
H
8.6
9.5
|
L
 3.0%
H
7.9
9.6
|
L
 -45.2%
H
7.9
16.6
|
L
 1163.8%
H
0.4
30.0
|
L
 50.3%
H
0.4
30.0
|
L
 -60.4%
H
0.4
30.0
|
L
 -64.5%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
612.5
|
7.6
|
L
 3.0%
H
7.5
7.9
|
L
 8.7%
H
6.9
7.9
|
L
 2.2%
H
6.6
8.0
|
L
 -14.5%
H
6.6
9.2
|
L
 -2.3%
H
4.6
9.7
|
L
 28.3%
H
3.5
9.7
|
L
 -57.2%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,053.7
|
26.0
|
L
 -0.9%
H
25.4
27.0
|
L
 -2.4%
H
24.4
31
|
L
 -6.0%
H
24.4
31
|
L
 -28.0%
H
24.4
38.4
|
L
 82.1%
H
10.4
47.7
|
L
 58.7%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
411.0
|
61.5
|
L
 1.9%
H
59.7
62.5
|
L
 6.8%
H
53.9
62.5
|
L
 10.9%
H
50.7
62.5
|
L
 -18.1%
H
50.7
76.1
|
L
 106.7%
H
26.1
105
|
L
 367.7%
H
1.4
105
|
L
 50.9%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
23.3
|
1.4
|
L
 5.3%
H
1.4
1.4
|
L
 1.5%
H
1.3
1.6
|
L
 -2.1%
H
1.3
1.7
|
L
 0.7%
H
1.3
2.5
|
L
 12.9%
H
0.8
4.1
|
L
 -29.3%
H
0.7
9.7
|
L
 -92.6%
H
0.7
36.5
|
L
 -98.1%
H
0.7
135.5
|
| Moderna |
|
20,410.5
|
51.7
|
L
 -1.7%
H
51.6
54.0
|
L
 -1.6%
H
51.4
57.9
|
L
 22.4%
H
42.0
59.6
|
L
 72.7%
H
29.0
59.6
|
L
 49.3%
H
22.3
59.6
|
L
 -65.5%
H
22.3
170.5
|
L
 -64.0%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
461.1
|
3.2
|
L
 2.3%
H
3
3.2
|
L
 -11.3%
H
3
3.8
|
L
 6.4%
H
2.9
3.9
|
L
 -14.2%
H
2.9
4.1
|
L
 28.6%
H
1.7
4.1
|
L
 -79.7%
H
1.7
16.6
|
L
 -91.8%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
84.3
|
0.8
|
L
 -3.7%
H
0.8
0.8
|
L
 1.3%
H
0.7
0.9
|
L
 9.7%
H
0.6
0.9
|
L
 -47.0%
H
0.6
1.7
|
L
 -76.0%
H
0.6
3.3
|
L
 -81.2%
H
0.6
5.5
|
L
 -86.5%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
8.1
|
0.7
|
L
 -12.2%
H
0.7
0.7
|
L
 -21.7%
H
0.7
0.9
|
L
 -18.8%
H
0.6
0.9
|
L
 -36.3%
H
0.6
1.6
|
L
 -85.1%
H
0.6
5.3
|
L
 -99.7%
H
0.6
284.4
|
L
H
0.6
1200
|
L
H
0.6
1200
|
| Mesoblast Ltd (ADR) |
|
1,878.7
|
14.6
|
L
 0.2%
H
14.5
14.8
|
L
 -8.0%
H
14.5
16.0
|
L
 -12.5%
H
13.5
17.3
|
L
 -17.7%
H
13.5
21.5
|
L
 7.6%
H
9.6
21.5
|
L
 367.3%
H
1.0
22
|
L
 51.2%
H
1.0
22
|
L
 62%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
161.6
|
4.3
|
L
 2.4%
H
4.2
4.3
|
L
 -13.6%
H
4.1
5.3
|
L
 -6.1%
H
4.1
5.4
|
L
 5.9%
H
4.0
5.4
|
L
 -0.2%
H
3.4
5.4
|
L
 -26.3%
H
3.3
12.7
|
L
 -81.7%
H
3.3
32.0
|
L
 -86.0%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
62.1
|
0.4
|
L
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 5.4%
H
0.4
0.5
|
L
 -82.2%
H
0.2
2.4
|
L
 -85.1%
H
0.2
3.1
|
L
 -54.1%
H
0.2
5.0
|
L
 -90.6%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
317.7
|
2.5
|
L
 7.7%
H
2.4
2.5
|
L
 1.6%
H
2.2
2.7
|
L
 14.6%
H
2.2
3.1
|
L
 32.1%
H
1.8
3.1
|
L
 126.1%
H
0.6
3.1
|
L
 13.6%
H
0.6
4.7
|
L
 -83.0%
H
0.6
15
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
164.1
|
2.3
|
L
 2.2%
H
2.3
2.4
|
L
 -7.6%
H
2.2
2.7
|
L
 17.3%
H
2.0
2.8
|
L
 25.5%
H
1.7
2.8
|
L
 39.2%
H
1.3
2.8
|
L
 -39.1%
H
1.3
16.2
|
L
 -95.3%
H
1.3
49.9
|
L
H
1.3
79.2
|
| MetaVia Inc |
|
5.3
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 3.2%
H
1.3
1.7
|
L
 -2.4%
H
1.3
1.7
|
L
 -80.8%
H
1.3
10
|
L
 -90.2%
H
1.3
23.1
|
L
 -97.3%
H
1.3
83.6
|
L
 -100.0%
H
1.3
17344.8
|
L
H
1.3
1424940
|
| Intellia Therapeutics Inc |
|
1,566.5
|
13.3
|
L
 3.9%
H
12.9
13.4
|
L
 -1.3%
H
12.6
14.2
|
L
 11.7%
H
11.7
15.5
|
L
 45.1%
H
8.7
17.1
|
L
 45.1%
H
5.9
28.3
|
L
 -67.6%
H
5.9
47.5
|
L
 -80.5%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,885.3
|
100.3
|
L
 2.4%
H
98.0
100.9
|
L
 0.9%
H
96.1
103.9
|
L
 -0.5%
H
96.1
107.6
|
L
 -4.5%
H
95.5
113.0
|
L
 30.2%
H
55.5
113.0
|
L
 257.1%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,631.0
|
10.0
|
L
 -2.3%
H
10.0
10.5
|
L
 0.3%
H
9.8
11.1
|
L
 15.1%
H
8.5
12.0
|
L
 52.1%
H
6.4
12.0
|
L
 25.3%
H
5.0
12.0
|
L
 69.7%
H
3.5
23.9
|
L
 -95.4%
H
3.5
277.8
|
L
 -90.0%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
8.0
|
1.9
|
L
 1.1%
H
1.9
2
|
L
 -10.7%
H
1.9
2.2
|
L
 -9.0%
H
1.9
2.3
|
L
 -46.7%
H
1.9
3.8
|
L
 -100.0%
H
1.9
53600
|
L
 -100.0%
H
1.9
1750000
|
L
 -100.0%
H
1.9
5770000
|
L
H
1.9
32000000
|
| Insight Molecular Diagnostics Inc |
|
136.2
|
4.8
|
L
 -3.3%
H
4.6
5.0
|
L
 -12.8%
H
4.6
5.6
|
L
 -14.7%
H
4.6
6.2
|
L
 -5.4%
H
4.6
7.5
|
L
 27.0%
H
2.3
8.5
|
L
 18.8%
H
1.9
8.5
|
L
 -95.2%
H
1.9
125
|
L
 -95.9%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
87.3
|
1.7
|
L
 2.4%
H
1.6
1.7
|
L
 2.4%
H
1.5
1.8
|
L
 -2.9%
H
1.5
1.9
|
L
 -10.1%
H
1.5
3.2
|
L
 12.6%
H
1.0
3.4
|
L
 -2.9%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
109.8
|
1.0
|
L
 4.1%
H
1.0
1.0
|
L
 -3.8%
H
1.0
1.1
|
L
 -3.8%
H
0.9
1.2
|
L
 10.9%
H
0.8
1.3
|
L
 64.5%
H
0.3
1.5
|
L
 -23.3%
H
0.3
3.4
|
L
 -67.0%
H
0.3
4.8
|
L
 -64.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
15.2
|
1.9
|
L
 -5%
H
1.9
2.0
|
L
 18.8%
H
1.5
2.5
|
L
 -1.0%
H
1.4
2.5
|
L
 -15.2%
H
1.1
3.0
|
L
 -30.7%
H
1.0
3.3
|
L
 -89.6%
H
1.0
36.3
|
L
 -99.5%
H
1.0
491.3
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.9
|
1.9
|
L
 4.4%
H
1.8
1.9
|
L
 2.7%
H
1.8
2.0
|
L
 -6%
H
1.8
2.3
|
L
 -3.6%
H
1.7
3.4
|
L
 -63.1%
H
0.3
5.3
|
L
 -91.8%
H
0.3
28.0
|
L
 -98.6%
H
0.3
140.2
|
L
 -99.6%
H
0.3
1197.6
|
| Passage Bio Inc |
|
24.2
|
7.6
|
L
 1.3%
H
7.5
8.1
|
L
 -10.1%
H
7.2
9.2
|
L
 -14.3%
H
7.2
9.8
|
L
 -24.9%
H
7.2
20
|
L
 -2.2%
H
5.1
20
|
L
 -65.0%
H
5.1
35.8
|
L
 -98.2%
H
5.1
416
|
L
H
5.1
764.6
|
| Vaxcyte Inc |
|
7,856.6
|
54.6
|
L
 0.0%
H
53.6
55.4
|
L
 -7.9%
H
53.2
60.5
|
L
 0.9%
H
52.9
65
|
L
 23.1%
H
42.4
65
|
L
 -26.6%
H
27.7
76.6
|
L
 40.3%
H
27.7
121.1
|
L
 101.7%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
374.6
|
5.4
|
L
 1.9%
H
5.3
5.5
|
L
 -4.6%
H
5.3
6.7
|
L
 -15.8%
H
5.0
7.1
|
L
 -0.9%
H
4.2
7.8
|
L
 125.8%
H
0.9
7.8
|
L
 -60.5%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,252.5
|
3.5
|
L
 0.9%
H
3.5
3.6
|
L
 6.6%
H
3.3
3.6
|
L
 -28.2%
H
3.2
5.5
|
L
 -7.1%
H
3.2
5.5
|
L
 96.7%
H
1.1
5.5
|
L
 221.8%
H
0.7
5.5
|
L
 -62.8%
H
0.7
9.6
|
L
 -89.6%
H
0.7
39.5
|
| Phio Pharma Corp |
|
14.6
|
1.3
|
L
 7.7%
H
1.2
1.3
|
L
 8.6%
H
1.1
1.3
|
L
 -23.6%
H
1.0
1.6
|
L
 15.6%
H
0.8
1.9
|
L
 -2.3%
H
0.8
4.2
|
L
 -97.5%
H
0.6
110.4
|
L
 -99.6%
H
0.6
348.8
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
83.0
|
1.4
|
L
H
1.4
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 21.6%
H
1.1
1.4
|
L
 8.9%
H
1.1
1.4
|
L
 -12.3%
H
1.1
2.0
|
L
 -95.1%
H
1.1
30.9
|
L
 -96.5%
H
1.1
42.3
|
L
H
1.1
43.9
|
| Pluri Inc |
|
33.8
|
3.4
|
L
 -0.9%
H
3.3
3.4
|
L
 2.4%
H
3.2
3.7
|
L
 -5.6%
H
3.2
3.8
|
L
 10.5%
H
2.8
3.9
|
L
 -27.1%
H
2.8
7.1
|
L
 -52.3%
H
0.7
8.6
|
L
 -92.4%
H
0.7
47.1
|
L
 -97.3%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
223.2
|
3.6
|
L
 7.6%
H
3.2
3.7
|
L
 9.9%
H
3.0
4
|
L
 59.2%
H
2.1
4
|
L
 83.0%
H
1.8
4
|
L
 379.7%
H
0.6
4.2
|
L
 -45.6%
H
0.6
8.6
|
L
 -93.9%
H
0.6
62.8
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
648.2
|
3.6
|
L
 -1.6%
H
3.6
3.8
|
L
 -10.5%
H
3.6
4.4
|
L
 8.8%
H
3.2
4.8
|
L
 -11.1%
H
3.2
4.8
|
L
 100.6%
H
1.1
6.9
|
L
 -72.3%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
310.0
|
2.2
|
L
 -2.7%
H
2.2
2.3
|
L
 -4.8%
H
2.2
2.6
|
L
 10.6%
H
2.0
2.6
|
L
 5.3%
H
1.7
2.6
|
L
 123.5%
H
0.5
7.1
|
L
 -82.7%
H
0.5
13.8
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
494.2
|
9.2
|
L
 -0.3%
H
9.1
9.3
|
L
 -4.3%
H
9.0
10.3
|
L
 2.5%
H
8.2
10.3
|
L
 -7.9%
H
8.2
10.5
|
L
 -33.2%
H
4.3
14.0
|
L
 -81.3%
H
4.3
79.7
|
L
 -62.9%
H
4.3
79.8
|
L
 -74.2%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
8.7
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -28.9%
H
0.4
0.5
|
L
 -66.4%
H
0.4
3.3
|
L
 -91.2%
H
0.4
15.8
|
L
 -99.4%
H
0.4
88
|
L
 -99.9%
H
0.4
899.5
|
L
 -99.8%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
6,099.5
|
95.6
|
L
 3.5%
H
92.6
96.3
|
L
 3.8%
H
90.9
98.3
|
L
 17.3%
H
77
98.3
|
L
 0.8%
H
77
98.3
|
L
 74.5%
H
39.6
98.3
|
L
 297.5%
H
13.7
98.3
|
L
 210.1%
H
6.9
98.3
|
L
H
4.5
98.3
|
| PureTech Health Plc ADR |
|
395.6
|
16.4
|
L
 -1.7%
H
16.3
16.4
|
L
 -2.6%
H
16.3
17.7
|
L
 -6.3%
H
16.3
18.5
|
L
 -3.3%
H
16.3
19.9
|
L
 -6.2%
H
13.3
20
|
L
 -42.4%
H
13.3
34
|
L
 -68.3%
H
13.3
65.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
5.6
|
0.1
|
L
 -9.1%
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -50%
H
0.1
0.2
|
L
 -97.4%
H
0.1
4
|
L
 -93.1%
H
0.1
4.6
|
L
 -88.2%
H
0.1
4.6
|
L
 -99.7%
H
0.1
122.0
|
L
H
0.1
122.0
|
| uniQure NV |
|
1,028.0
|
16.4
|
L
 5.9%
H
15.5
16.6
|
L
 15.2%
H
15.0
19.2
|
L
 -19.8%
H
8.7
25.4
|
L
 -19.5%
H
8.7
28.8
|
L
 15.8%
H
7.8
71.5
|
L
 -14.7%
H
3.7
71.5
|
L
 -51.4%
H
3.7
71.5
|
L
 39.3%
H
3.7
82.5
|
| Rain Oncology Inc |
|
102.9
|
2.8
|
L
 -3.4%
H
2.8
2.9
|
L
 1.1%
H
2.7
3.2
|
L
 1.8%
H
2.5
3.2
|
L
 -53.2%
H
2.1
8.5
|
L
 35.4%
H
1.5
9.2
|
L
 -64.7%
H
0.8
10.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
128.8
|
1.3
|
L
H
1.3
1.3
|
L
 1.5%
H
1.3
1.4
|
L
 6.5%
H
1.2
1.4
|
L
 -9.0%
H
1.1
1.5
|
L
 -12.6%
H
0.4
3.9
|
L
 -77.8%
H
0.4
8.8
|
L
 -99.4%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
524.4
|
4.8
|
L
 2.1%
H
4.8
4.9
|
L
 9.5%
H
4.4
5.5
|
L
 47.7%
H
3.2
5.5
|
L
 41.6%
H
3
5.5
|
L
 -44.9%
H
2.2
8.9
|
L
 -73.2%
H
2.2
32.5
|
L
 -91.5%
H
2.2
58.7
|
L
 -83.0%
H
2.2
67.5
|
| Replimune Grp Inc |
|
598.7
|
7.3
|
L
 1.5%
H
7.2
7.5
|
L
 -10.2%
H
6.9
9.1
|
L
 -9.0%
H
6.8
9.1
|
L
 -27.1%
H
6.8
10.3
|
L
 -37.8%
H
2.7
13.2
|
L
 -62.6%
H
2.7
24.8
|
L
 -78.7%
H
2.7
40.2
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
4.6
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -4.7%
H
1.2
1.4
|
L
 -16.3%
H
1.2
1.5
|
L
 -68.0%
H
1.2
5.8
|
L
 -97.0%
H
1.2
44.8
|
L
 -100.0%
H
1.2
9561.6
|
L
 -100.0%
H
1.2
2276064
|
L
H
1.2
2276064
|
| Relay Therapeutics Inc |
|
1,840.9
|
10.3
|
L
 -0.6%
H
10.2
10.8
|
L
 4.2%
H
9.6
11.5
|
L
 15.3%
H
8.4
11.5
|
L
 21.5%
H
7.0
11.5
|
L
 181.4%
H
1.8
11.5
|
L
 -37.6%
H
1.8
19.2
|
L
 -73.9%
H
1.8
40.7
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
8.9
|
9.7
|
L
 -0.4%
H
9.5
9.8
|
L
 1.5%
H
8.9
10.0
|
L
 5.8%
H
8.6
10.6
|
L
 7.4%
H
6.1
12.6
|
L
 -55.3%
H
6.1
46.8
|
L
 -100.0%
H
6.1
362374.6
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,795.9
|
3.4
|
L
 -0.6%
H
3.4
3.5
|
L
 -1.7%
H
3.2
3.6
|
L
 -2.6%
H
3.0
4.1
|
L
 -19.1%
H
3.0
5.2
|
L
 -46.5%
H
3.0
7.2
|
L
 -54.5%
H
3.0
16.7
|
L
H
3.0
42.8
|
L
H
3.0
42.8
|
| Rhythm Pharma Inc |
|
6,093.8
|
89.2
|
L
 2.1%
H
87
89.6
|
L
 -4.6%
H
82
94.9
|
L
 -9%
H
82
104.5
|
L
 -20.7%
H
82
115.1
|
L
 75.1%
H
45.9
122.2
|
L
 389.5%
H
15.5
122.2
|
L
 237.8%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
196.1
|
4.1
|
L
 -0.7%
H
4.1
4.3
|
L
 8.7%
H
3.7
5.2
|
L
 7.0%
H
3.5
5.2
|
L
 3%
H
3.4
5.2
|
L
 155.9%
H
1
6.6
|
L
 707.8%
H
0.4
6.6
|
L
 -58.3%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
888.7
|
3.3
|
L
 -0.9%
H
3.3
3.5
|
L
 5.7%
H
3
3.5
|
L
 -13.5%
H
3
4.5
|
L
 -34.5%
H
3
5.3
|
L
 13.7%
H
1.3
6.6
|
L
 -2.6%
H
1.3
12
|
L
 -88.7%
H
1.3
33.8
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
96.1
|
2.0
|
L
H
2.0
2.0
|
L
 -2.0%
H
2.0
2.5
|
L
 -4.8%
H
2.0
2.5
|
L
 -28.9%
H
1.9
3.0
|
L
 -28.7%
H
1.2
5.0
|
L
 -92.4%
H
1.2
42.2
|
L
 -96.2%
H
1.2
146.2
|
L
 -85.6%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
102.1
|
1.8
|
L
H
1.8
1.8
|
L
 1.7%
H
1.7
1.8
|
L
 -10.4%
H
1.7
2.2
|
L
 -0.6%
H
1.7
2.2
|
L
 -7.2%
H
1.6
2.4
|
L
 -60.5%
H
1.5
5.7
|
L
 -96.5%
H
1.5
57.9
|
L
H
1.5
86.6
|
| Sangamo Therapeutics Inc |
|
141.2
|
0.4
|
L
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.6
|
L
 -13.6%
H
0.3
0.6
|
L
 -61.2%
H
0.3
1.0
|
L
 -82.4%
H
0.3
3.2
|
L
 -96.8%
H
0.3
13.9
|
L
 -93.1%
H
0.3
27.5
|
| Solid Biosciences Inc |
|
592.1
|
7.6
|
L
 4.0%
H
7.4
7.8
|
L
 12.6%
H
6.6
8.7
|
L
 22.8%
H
5.2
8.7
|
L
 33.1%
H
4.9
8.7
|
L
 49.3%
H
2.4
8.7
|
L
 58.3%
H
1.8
15.1
|
L
 -94.7%
H
1.8
123.8
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
12,429.2
|
16.0
|
L
 -0.6%
H
15.7
16.4
|
L
 6.1%
H
15.0
16.7
|
L
 7.2%
H
14.6
16.8
|
L
 -7.8%
H
13.8
20.2
|
L
 -22.9%
H
13.8
36.9
|
L
 877.4%
H
1.3
36.9
|
L
 150.5%
H
0.7
36.9
|
L
 138.9%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,108.9
|
23.9
|
L
 1.7%
H
23.5
24.3
|
L
 8.3%
H
22.2
25.2
|
L
 16.8%
H
19.2
25.2
|
L
 14.5%
H
19.2
25.2
|
L
 84.6%
H
8.6
25.2
|
L
 7.2%
H
8.6
25.3
|
L
 1.5%
H
8.6
29.9
|
L
 94.5%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
38.7
|
30.7
|
L
 -4.9%
H
29.7
32.5
|
L
 2.3%
H
28.2
32.7
|
L
 237.7%
H
8.8
36.8
|
L
 289.1%
H
8.0
36.8
|
L
 228.0%
H
5
36.8
|
L
 10.4%
H
5
38.8
|
L
 -90.3%
H
5
327.2
|
L
H
5
530
|
| Senti Biosciences Inc |
|
25.2
|
1.0
|
L
 3.2%
H
0.9
1.0
|
L
H
0.9
1.0
|
L
 15.7%
H
0.8
1.0
|
L
 -20.7%
H
0.8
1.3
|
L
 -72.5%
H
0.8
5.1
|
L
 -92.4%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
62.9
|
58.8
|
L
 -2.1%
H
58.5
61.7
|
L
 5.3%
H
52.5
68.1
|
L
 -11.3%
H
48.1
68.1
|
L
 -27.1%
H
48.1
91.1
|
L
 134.1%
H
4.3
240
|
L
 -65.3%
H
4.3
446.3
|
L
 -96.4%
H
4.3
1695
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
146.5
|
2.6
|
L
 0.8%
H
2.6
2.6
|
L
 13.0%
H
2.2
2.6
|
L
 8.8%
H
2.1
2.6
|
L
 13.5%
H
2.1
2.7
|
L
 233.3%
H
0.5
3.2
|
L
 76.9%
H
0.5
3.2
|
L
 -84.5%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
4,644.7
|
40.4
|
L
 1.1%
H
39.7
40.8
|
L
 -10.7%
H
39.7
46.1
|
L
 -12.1%
H
39.7
48.8
|
L
 -10.6%
H
39.7
49.8
|
L
 16.9%
H
22.7
49.8
|
L
 291.4%
H
5.6
49.8
|
L
 -40.6%
H
4.3
70
|
L
H
4.3
70
|
| Surrozen Inc |
|
216.1
|
25.2
|
L
H
25.1
25.9
|
L
 -6.8%
H
23.4
29.5
|
L
 3.0%
H
23.4
29.6
|
L
 16.6%
H
16.8
29.6
|
L
 117.5%
H
5.9
29.6
|
L
 2701.1%
H
0.3
29.6
|
L
H
0.3
29.6
|
L
H
0.3
29.6
|
| Stoke Therapeutics Inc |
|
1,917.4
|
33.6
|
L
 1.1%
H
32.7
34.3
|
L
 -5.4%
H
32.7
40.2
|
L
 5.2%
H
30.5
40.2
|
L
 1.8%
H
25.2
40.2
|
L
 290.4%
H
5.4
40.2
|
L
 266.9%
H
3.4
40.2
|
L
 -35.5%
H
3.4
53.7
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
382.2
|
6.0
|
L
 0.8%
H
6
6.3
|
L
 0.8%
H
5.6
6.3
|
L
 56.5%
H
3.8
6.3
|
L
 97.4%
H
2.8
6.3
|
L
 407.6%
H
0.7
6.3
|
L
 115.7%
H
0.7
11.8
|
L
 -84.2%
H
0.7
40.9
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
3.2
|
2.5
|
L
 2.5%
H
2.4
2.6
|
L
 19.5%
H
1.9
3.6
|
L
 -30.2%
H
1.9
3.6
|
L
 -25.3%
H
1.4
8.6
|
L
 -67.6%
H
1.4
17.7
|
L
H
1.4
2076
|
L
H
1.4
2076
|
L
H
1.4
2076
|
| Alaunos Therapeutics Inc |
|
7.7
|
3.5
|
L
 4.9%
H
3.4
3.5
|
L
 -4.2%
H
3.0
3.7
|
L
 34.6%
H
2.5
3.7
|
L
 -17.8%
H
2.3
4.4
|
L
 142.0%
H
1.3
6.2
|
L
 592%
H
0.0
6.2
|
L
 -20.3%
H
0.0
6.2
|
L
 -55.4%
H
0.0
9.2
|
| Tscan Therapeutics Inc |
|
60.9
|
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 -4.5%
H
1.0
1.3
|
L
 15.1%
H
0.9
1.3
|
L
 11.5%
H
0.9
1.3
|
L
 -38.5%
H
0.9
2.6
|
L
 -59.2%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
7,702.2
|
49.2
|
L
 -3.2%
H
49.1
52.3
|
L
 -8.7%
H
49.1
55.1
|
L
 -17.9%
H
49.1
60.1
|
L
 -16.1%
H
49.1
72.2
|
L
 -20.8%
H
46.0
72.2
|
L
 -32.3%
H
46.0
89.9
|
L
 -50.4%
H
46.0
136.0
|
L
 113.9%
H
22.8
136.0
|
| Terns Pharma Inc |
|
5,064.2
|
46.6
|
L
 0.1%
H
46.4
48.0
|
L
 8.7%
H
41.7
48.0
|
L
 23.2%
H
37.4
48.0
|
L
 5.8%
H
33.4
48.0
|
L
 1364.2%
H
1.9
48.3
|
L
 405.5%
H
1.9
48.3
|
L
 87.4%
H
1.5
48.3
|
L
H
1.5
48.3
|
| Instil Bio Inc |
|
55.3
|
8.2
|
L
 -1.2%
H
8.2
8.4
|
L
 -8%
H
8.0
9.3
|
L
 2.1%
H
7.8
9.8
|
L
 -26.6%
H
5.7
12.9
|
L
 -59.0%
H
5.7
42.8
|
L
 1136.4%
H
0.3
92
|
L
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
2,558.4
|
17.9
|
L
 3.6%
H
17.3
18.5
|
L
 5.8%
H
16.1
18.5
|
L
 39.0%
H
10.8
18.5
|
L
 96.6%
H
8.3
18.5
|
L
 819.5%
H
1.0
18.5
|
L
 318.9%
H
1.0
18.5
|
L
H
1.0
18.8
|
L
H
1.0
18.8
|
| Entrada Therapeutics Inc |
|
501.1
|
13.1
|
L
 3.2%
H
12.6
13.2
|
L
 4.1%
H
12.3
13.7
|
L
 20.3%
H
10.6
13.7
|
L
 18.7%
H
9.3
13.7
|
L
 21.1%
H
4.9
13.7
|
L
 -3.8%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,458.0
|
11.4
|
L
 3.3%
H
11.1
11.7
|
L
 -14.5%
H
10.8
13.3
|
L
 9.3%
H
9.8
13.6
|
L
 -9.8%
H
9.8
13.6
|
L
 68.4%
H
4.9
14.4
|
L
 521.3%
H
1.0
14.4
|
L
 294.8%
H
0.5
14.4
|
L
H
0.5
14.4
|
| Taysha Gene Therapies Inc |
|
1,246.3
|
4.6
|
L
 1.3%
H
4.5
4.6
|
L
 -0.4%
H
4.3
4.8
|
L
H
4.3
5.1
|
L
 -21.0%
H
4.3
6.0
|
L
 164.5%
H
1.1
6.0
|
L
 417.0%
H
0.5
6.0
|
L
 -82.8%
H
0.5
27.5
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
2,715.5
|
44.3
|
L
 2.3%
H
43.6
45.3
|
L
 -5.7%
H
42.5
49
|
L
 -9.8%
H
42.5
57.9
|
L
 42.6%
H
30.2
57.9
|
L
 10.8%
H
23.3
57.9
|
L
 161.5%
H
11.5
60.9
|
L
 -69.3%
H
11.5
150.3
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
2,063.2
|
16.2
|
L
 -14.1%
H
16.0
19.3
|
L
 -22.4%
H
16.0
21.3
|
L
 -10.9%
H
16.0
23.3
|
L
 2.5%
H
15.4
23.6
|
L
 56.2%
H
6.8
23.6
|
L
 -66.8%
H
6.8
63.6
|
L
 -90.5%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
920.6
|
18.9
|
L
 2.6%
H
18.6
19.1
|
L
 -7.6%
H
17.9
21.1
|
L
 -5.9%
H
17.9
22.5
|
L
 -17.2%
H
17.9
24.7
|
L
 70.8%
H
3.4
30
|
L
 96.4%
H
3.4
30
|
L
 -2.7%
H
3.4
30
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
2,862.8
|
40.1
|
L
 0.4%
H
39.4
41.0
|
L
 2.7%
H
38
45.4
|
L
 -5.0%
H
38.0
45.4
|
L
 -18.5%
H
38.0
56.1
|
L
 43.3%
H
18.5
56.1
|
L
 462.7%
H
6.0
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,526.2
|
9.6
|
L
 3.1%
H
9.3
9.6
|
L
H
9.1
10.3
|
L
 27.8%
H
7.3
10.9
|
L
 42.1%
H
5.6
10.9
|
L
 33.6%
H
4.2
10.9
|
L
 -59.4%
H
4.2
27.5
|
L
 -81.7%
H
4.2
58.3
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
581.7
|
14.0
|
L
 3.7%
H
13.6
14.3
|
L
 -7.3%
H
13.2
16.7
|
L
 9.6%
H
12.6
17.1
|
L
 3.7%
H
10.3
18.6
|
L
 1456.7%
H
0.1
50.0
|
L
 178.0%
H
0.1
50.0
|
L
 -65.7%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
421.8
|
5.6
|
L
H
5.5
5.7
|
L
 -12.2%
H
5.5
6.8
|
L
 -3.8%
H
5.5
6.8
|
L
 -39.6%
H
5.5
9.4
|
L
 -19.5%
H
4.0
11.2
|
L
 8.5%
H
2.1
15.2
|
L
 -79.8%
H
2.1
59.2
|
L
 -65.7%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
25.0
|
0.6
|
L
 3.3%
H
0.6
0.6
|
L
 3.3%
H
0.6
0.6
|
L
 23.5%
H
0.5
0.7
|
L
 -85.7%
H
0.4
4.5
|
L
 -76.7%
H
0.4
5.1
|
L
 -86.2%
H
0.4
24.7
|
L
 -99.1%
H
0.4
106.5
|
L
 -99.7%
H
0.4
270
|
| Voyager Therapeutics Inc |
|
263.4
|
4.4
|
L
 -0.9%
H
4.3
4.6
|
L
 13.3%
H
3.9
5.5
|
L
 30.4%
H
3.3
5.5
|
L
 1.4%
H
3.3
5.5
|
L
 13.3%
H
2.6
5.6
|
L
 -44.9%
H
2.6
14.3
|
L
 -23.8%
H
2.5
14.3
|
L
 -55.4%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
916.5
|
10.6
|
L
 -0.6%
H
10.4
10.7
|
L
 0.3%
H
10.3
11.8
|
L
 4.7%
H
10
12.2
|
L
 22.7%
H
8.0
12.2
|
L
 55.4%
H
5.4
12.3
|
L
 -5.8%
H
3.6
17.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
2,373.9
|
12.6
|
L
 -3.2%
H
12.6
13.4
|
L
 -3.9%
H
12.6
14.3
|
L
 -0.6%
H
12.5
15.5
|
L
 -21.7%
H
12.5
19.5
|
L
 23.4%
H
5.3
21.7
|
L
 216.0%
H
3.2
21.7
|
L
 25.8%
H
1.2
21.7
|
L
 -35.2%
H
1.2
56
|
| XBiotech Inc |
|
70.7
|
2.3
|
L
 0.4%
H
2.3
2.3
|
L
 -1.3%
H
2.3
2.5
|
L
 -5.3%
H
2.2
2.5
|
L
 -8.3%
H
2.2
2.7
|
L
 -29.9%
H
2.1
3.6
|
L
 -31.4%
H
2.1
10.0
|
L
 -88.5%
H
2.1
20.2
|
L
 -72.6%
H
2.1
26.4
|
| Exicure Inc |
|
30.3
|
4.8
|
L
 13.1%
H
4.2
4.9
|
L
 14.5%
H
3.9
4.9
|
L
 16.4%
H
3.5
4.9
|
L
 -17.1%
H
3.5
6.6
|
L
 -63.0%
H
3.1
15.9
|
L
 -8.7%
H
0.3
36
|
L
 -98.7%
H
0.3
402.0
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
936.3
|
5.4
|
L
 -0.6%
H
5.4
5.7
|
L
 -6.5%
H
5.4
5.9
|
L
 -20.4%
H
5.4
7.1
|
L
 -23.0%
H
5.4
8.4
|
L
 12.7%
H
3.8
10.1
|
L
 317.7%
H
1.3
10.1
|
L
 19.1%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
319.1
|
3.7
|
L
 -1.1%
H
3.5
3.7
|
L
 -2.9%
H
3.5
4.8
|
L
 7.0%
H
2.8
4.8
|
L
 -2.9%
H
2.8
4.8
|
L
 973.5%
H
0.2
6.6
|
L
 301.1%
H
0.2
6.6
|
L
 -61.1%
H
0.2
10.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
896.2
|
12.2
|
L
 1.8%
H
11.8
12.4
|
L
 8.0%
H
11.2
12.4
|
L
 5.4%
H
10.6
14.5
|
L
 -27.2%
H
10.6
16.9
|
L
 -4.2%
H
6.9
18.7
|
L
 -56.7%
H
6.9
30.2
|
L
 -73.8%
H
6.9
47.4
|
L
 4.1%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.9
|
3.7
|
L
 -4.4%
H
3.7
4.0
|
L
 -8.4%
H
3.6
4.2
|
L
 -42.3%
H
3.6
6.9
|
L
 -74.2%
H
3.6
16.2
|
L
 -99.4%
H
3.6
841.8
|
L
 -100.0%
H
3.6
10204423.7
|
L
 -100.0%
H
3.6
67850460
|
L
 -100.0%
H
3.6
67850460
|
| Zentalis Pharma Inc |
|
178.7
|
2.8
|
L
 1.9%
H
2.7
2.8
|
L
 20%
H
2.3
3.1
|
L
 15.5%
H
2.1
3.1
|
L
 97.1%
H
1.3
4.0
|
L
 55.9%
H
1.0
4.0
|
L
 -84.9%
H
1.0
31.5
|
L
 -94.0%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
597.7
|
6.3
|
L
 2.1%
H
6.2
6.4
|
L
 -9.6%
H
6.2
7.4
|
L
 3.6%
H
5.8
7.4
|
L
 54.8%
H
3.9
7.4
|
L
 392.2%
H
1.0
7.4
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,102.2
|
19
|
L
 3.4%
H
18.6
19.1
|
L
 -2.8%
H
18.3
19.8
|
L
 -5.1%
H
17.1
20.3
|
L
 9.6%
H
16.0
20.3
|
L
 -50.3%
H
16.0
44.3
|
L
 -40.6%
H
13.5
44.3
|
L
 -86.6%
H
13.5
181.9
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
4,893.0
|
71.1
|
L
 -1.2%
H
71.1
73.4
|
L
 -2.7%
H
70.4
77.6
|
L
 4.9%
H
66
77.6
|
L
 -7.5%
H
60.4
84.6
|
L
 77.9%
H
26.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
| Intensity Therapeutics Inc |
|
15.8
|
6.3
|
L
 -7.8%
H
6.2
6.8
|
L
 -21.4%
H
6.2
8.0
|
L
H
5.4
8.1
|
L
 -41.0%
H
5.4
11.6
|
L
 -89.2%
H
4.6
62.5
|
L
 -93.8%
H
4.6
286
|
L
 -93.8%
H
4.6
286
|
L
 -93.8%
H
4.6
286
|
| Renovaro Biosciences Inc |
|
4.4
|
0.2
|
L
H
0.2
0.2
|
L
 -21.7%
H
0.2
0.2
|
L
 -75.3%
H
0.2
0.7
|
L
 -82%
H
0.2
1.1
|
L
 -97.8%
H
0.2
8.0
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
| Elutia Inc (Class A) |
|
45.7
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 1.9%
H
1.0
1.4
|
L
 59.7%
H
0.5
1.4
|
L
 -66.4%
H
0.5
3.5
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
162.1
|
4.1
|
L
 0.7%
H
4.1
4.4
|
L
 -8.5%
H
4.0
4.8
|
L
 -8.5%
H
4.0
5.3
|
L
 70.8%
H
2.2
5.8
|
L
 182.8%
H
1.0
9.1
|
L
 -98.9%
H
0.3
498.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
726.4
|
7.5
|
L
 -0.3%
H
7.3
7.7
|
L
 -2.2%
H
7.3
8.5
|
L
 -6.0%
H
7.3
9.1
|
L
H
6.8
9.1
|
L
 -37.7%
H
6.1
12.4
|
L
 0.5%
H
5.6
130.5
|
L
 0.5%
H
5.6
130.5
|
L
 0.5%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
479.5
|
6.6
|
L
 -1.4%
H
6.6
6.9
|
L
 -4.1%
H
6.3
8
|
L
 4.1%
H
6.0
8
|
L
 -32.7%
H
6.0
11.0
|
L
 114.0%
H
1.5
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
118.8
|
12.6
|
L
 -1.5%
H
12.5
13.7
|
L
 12.8%
H
11.3
14.8
|
L
 12.9%
H
10.6
14.8
|
L
 58.4%
H
7.6
14.9
|
L
 -48.8%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
202.6
|
7.8
|
L
 5.4%
H
7.5
8.0
|
L
 13.7%
H
6.6
9.3
|
L
 19.5%
H
6.1
9.3
|
L
 -13.2%
H
6.1
9.3
|
L
 -50.7%
H
6.0
16.8
|
L
 -99.4%
H
6.0
1386
|
L
 -99.8%
H
6.0
4752
|
L
H
6.0
25199.6
|
| Elevai Labs Inc |
|
2.7
|
4.9
|
L
 7.2%
H
4.6
5.2
|
L
 10.6%
H
4.0
5.2
|
L
 -40.3%
H
4.0
9.4
|
L
 -93.8%
H
4.0
79.9
|
L
 -98.6%
H
4.0
686.3
|
L
H
4.0
499117.9
|
L
H
4.0
499117.9
|
L
H
4.0
499117.9
|
| Spyre Therapeutics Inc |
|
3,423.6
|
43.6
|
L
 9.3%
H
40.7
43.8
|
L
 8.6%
H
39
43.8
|
L
 19%
H
35.0
45.8
|
L
 30.7%
H
28
45.8
|
L
 141.6%
H
10.9
45.8
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
| Neurogene Inc |
|
333.3
|
21.5
|
L
 0.1%
H
21.5
22.1
|
L
 -2.9%
H
19.9
23.8
|
L
 23.8%
H
16.8
26.4
|
L
 6.2%
H
15.9
26.4
|
L
 28.9%
H
6.9
37.3
|
L
 51.8%
H
6.9
74.5
|
L
 51.8%
H
6.9
74.5
|
L
 51.8%
H
6.9
74.5
|
| Cg Oncology Inc |
|
5,578.6
|
66.1
|
L
 2.8%
H
63.5
66.8
|
L
 6.8%
H
59.6
66.8
|
L
 28.3%
H
50.5
66.8
|
L
 66.2%
H
37.0
66.8
|
L
 137.7%
H
14.8
66.8
|
L
H
14.8
66.8
|
L
H
14.8
66.8
|
L
H
14.8
66.8
|
| FibroBiologics Inc |
|
19.6
|
0.3
|
L
 -6.5%
H
0.3
0.3
|
L
 -34.1%
H
0.3
0.5
|
L
 16%
H
0.2
0.5
|
L
 11.5%
H
0.2
0.5
|
L
 -71.6%
H
0.2
1.5
|
L
H
0.2
55
|
L
H
0.2
55
|
L
H
0.2
55
|
| Kyverna Therapeutics Inc |
|
541.8
|
9.1
|
L
 1.6%
H
9.0
9.3
|
L
 12.2%
H
8
9.7
|
L
 25.2%
H
7.3
9.7
|
L
 -16.0%
H
6.6
11.4
|
L
 263.6%
H
1.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
56.3
|
1.5
|
L
 2.7%
H
1.5
1.5
|
L
 1.4%
H
1.5
1.8
|
L
 2.7%
H
1.4
1.8
|
L
 -6.8%
H
1.4
1.9
|
L
 -22.7%
H
1.2
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
21.4
|
5.3
|
L
 -1.7%
H
4.9
6.2
|
L
 -27.6%
H
4.9
8.1
|
L
 -62.2%
H
4.9
15.4
|
L
 -73.4%
H
4.9
20.9
|
L
 -91.0%
H
4.9
75.5
|
L
H
4.9
1054.5
|
L
H
4.9
1054.5
|
L
H
4.9
1054.5
|
| NeOnc Tech Holdings Inc |
|
221.3
|
9.1
|
L
 5.0%
H
8.9
9.7
|
L
 -4.0%
H
8.5
10.1
|
L
 -11.3%
H
8.5
10.4
|
L
 -8.1%
H
6.4
11.4
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
382.7
|
12.2
|
L
 0.7%
H
12.0
12.5
|
L
 4.8%
H
11.2
12.7
|
L
 -5.1%
H
11.2
15.0
|
L
 -28.4%
H
11.2
21.8
|
L
 -51.9%
H
11.2
50.4
|
L
 -50.9%
H
11.2
50.4
|
L
 -50.9%
H
11.2
50.4
|
L
 -50.9%
H
11.2
50.4
|
| Boundless Bio Inc |
|
25.3
|
1.1
|
L
 1.8%
H
1.1
1.1
|
L
H
1.1
1.2
|
L
H
1.1
1.2
|
L
 -0.9%
H
1.0
1.4
|
L
 -32.7%
H
1.0
1.8
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
470.9
|
12.9
|
L
 -0.9%
H
12.7
13.8
|
L
 -7.1%
H
12.7
15
|
L
 -10.7%
H
12.7
16.3
|
L
 11.3%
H
8.6
16.3
|
L
 93.3%
H
3.4
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
431.1
|
7.4
|
L
 0.5%
H
7.2
7.6
|
L
 -7.4%
H
7.2
8.3
|
L
 -12.1%
H
7.2
8.8
|
L
 20.1%
H
6.0
9.3
|
L
 78.3%
H
2.7
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
8.3
|
2.5
|
L
 9.3%
H
2.2
2.5
|
L
 12.3%
H
2.0
2.5
|
L
 -19.3%
H
2.0
3.1
|
L
 -3.5%
H
1.9
5.3
|
L
 70.3%
H
1.0
5.8
|
L
 -70.4%
H
0.6
9.5
|
L
 -70.4%
H
0.6
9.5
|
L
 -70.4%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
156.6
|
6.4
|
L
 3.2%
H
6.3
6.7
|
L
 11.2%
H
5.5
7.8
|
L
 59.5%
H
3.9
7.8
|
L
 1.3%
H
3.6
7.8
|
L
 25.1%
H
1.5
7.8
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,358.7
|
30.3
|
L
 8.1%
H
29.2
31.2
|
L
 -1.0%
H
26.4
31.2
|
L
 -20.6%
H
26.4
41.0
|
L
 6.6%
H
26.4
44.9
|
L
 247.8%
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
| BioAge Labs Inc |
|
900.6
|
21.6
|
L
 15.2%
H
19.0
21.6
|
L
 6.3%
H
18.4
21.6
|
L
 10.2%
H
18.4
23
|
L
 73.1%
H
11.9
24
|
L
 395.9%
H
2.9
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
53.2
|
3.9
|
L
 4.0%
H
3.8
4.2
|
L
 28.9%
H
3.1
4.2
|
L
 62.4%
H
2.4
4.2
|
L
 22.8%
H
2.2
4.2
|
L
 -14.8%
H
1.7
5.3
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
5.5
|
L
 0.9%
H
5.3
5.6
|
L
 30%
H
4.2
7.8
|
L
 41.8%
H
3.5
7.8
|
L
 -19.1%
H
3.3
7.8
|
L
 137.4%
H
1.3
7.8
|
L
 137.4%
H
1.3
7.8
|
L
 137.4%
H
1.3
7.8
|
L
 137.4%
H
1.3
7.8
|
| Upstream Bio Inc |
|
512.8
|
9.5
|
L
 2.8%
H
9.3
9.6
|
L
 23.9%
H
7.6
9.8
|
L
 8.5%
H
7.3
9.8
|
L
 -65.1%
H
7.3
33.7
|
L
 -1.3%
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
13.1
|
0.5
|
L
 -3.6%
H
0.5
0.5
|
L
 35.9%
H
0.4
0.7
|
L
 -50%
H
0.4
1.7
|
L
 -71.0%
H
0.4
1.9
|
L
 -92.1%
H
0.4
8.9
|
L
 -92.1%
H
0.4
8.9
|
L
 -92.1%
H
0.4
8.9
|
L
 -92.1%
H
0.4
8.9
|
| Telix Pharma Ltd (ADR) |
|
2,635.7
|
7.8
|
L
 -0.9%
H
7.8
7.9
|
L
 3.5%
H
7.2
8.1
|
L
 19.0%
H
6.3
8.1
|
L
 -9.9%
H
6.3
8.5
|
L
 -55.0%
H
6.3
19.9
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,821.4
|
128
|
L
 4.9%
H
123.9
134.4
|
L
 -4.8%
H
120.7
143.8
|
L
 57.0%
H
78
151.2
|
L
 43.9%
H
72.2
151.2
|
L
 366.1%
H
18.2
151.2
|
L
 841.2%
H
11.2
151.2
|
L
 841.2%
H
11.2
151.2
|
L
 841.2%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
1,696.9
|
37.7
|
L
 1.1%
H
36.6
39.0
|
L
 5.0%
H
34.6
39.2
|
L
 0.5%
H
32.6
39.3
|
L
 -11.8%
H
32.5
45
|
L
 151.7%
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
| Zenas Biopharma Inc |
|
1,277.6
|
23.8
|
L
 -1%
H
21.5
24.0
|
L
 -5.9%
H
21.5
27.0
|
L
 -9.9%
H
21.5
29.6
|
L
 -27.0%
H
13.5
44.6
|
L
 127.3%
H
8.9
44.6
|
L
 127.3%
H
8.9
44.6
|
L
 127.3%
H
8.9
44.6
|
L
 127.3%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
1.9
|
0.1
|
L
 -7.7%
H
0.1
0.1
|
L
 -29.4%
H
0.1
0.2
|
L
 -42.9%
H
0.1
0.2
|
L
 -84%
H
0.1
0.8
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
| SpyGlass Pharma Inc |
|
932.6
|
28.0
|
L
 5.4%
H
26.4
28
|
L
 4.9%
H
26.2
29.1
|
L
 -0.8%
H
25.3
30.6
|
L
 6.0%
H
24.7
30.6
|
L
 6.0%
H
24.7
30.6
|
L
 6.0%
H
24.7
30.6
|
L
 6.0%
H
24.7
30.6
|
L
 6.0%
H
24.7
30.6
|
| AgomAb Therapeutics NV ADR |
|
706.8
|
14.4
|
L
 3.7%
H
14
14.4
|
L
 5.4%
H
13.2
15.5
|
L
 -6.4%
H
13.2
17.5
|
L
 -2.0%
H
13.2
17.5
|
L
 -2.0%
H
13.2
17.5
|
L
 -2.0%
H
13.2
17.5
|
L
 -2.0%
H
13.2
17.5
|
L
 -2.0%
H
13.2
17.5
|
| Generate Biomedicines Inc |
|
1,547.2
|
12.1
|
L
 -7.2%
H
12.1
13.1
|
L
 8.3%
H
11.6
13.7
|
L
 -4.0%
H
11
14.0
|
L
 -4.0%
H
11
14.0
|
L
 -4.0%
H
11
14.0
|
L
 -4.0%
H
11
14.0
|
L
 -4.0%
H
11
14.0
|
L
 -4.0%
H
11
14.0
|